Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
GN
Genelux Corporation Common Stock
GNLX
Mkt Cap
$109.4M
Volume
269.57K
Next Earnings
November 4th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
GN
GNLX
GN
Genelux Corporation Common Stock
GNLX
News
·
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
Mkt Cap
$112.2M
Volume
269.57K
Next Earnings
November 4th
Chart
Financials
Earnings
News
About
Insider
Filings
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
Genelux Corporation announced that its President, CEO, and Chairman Thomas Zindrick, along with CFO Matt Pulisic and Chief Medical Officer Dr. Jason Litten, will participate in a virtual fireside chat on January 19, 2026. The company is a late clinical-stage biopharmaceutical firm developing oncolytic immunotherapies, with its lead candidate Olvi-Vec currently in Phase 2 and Phase 3 clinical trials for ovarian cancer, non-small-cell lung cancer, and small-cell lung cancer.
GlobeNewswire Inc. · Jan 12, 2026
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
Genelux Corporation announced the appointment of Jason Litten, M.D., as Chief Medical Officer effective January 2, 2026. Dr. Litten brings over 20 years of biopharmaceutical experience and will oversee clinical development and medical strategy for Olvi-Vec, the company's oncolytic immunotherapy candidate currently in Phase 2/3 trials for ovarian and lung cancers.
GlobeNewswire Inc. · Jan 2, 2026
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
Genelux Corporation, a late clinical-stage immuno-oncology company, announced that its President, Chairman and CEO will discuss the company's clinical-stage programs, recent announcements, and upcoming milestones at the H.C. Wainwright Global Healthcare Conference.
GlobeNewswire Inc. · Sep 3, 2024
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
Genelux Corporation, a late clinical-stage immuno-oncology company, announced that its President, CEO and Chairman will discuss the company's clinical-stage programs, recent announcements, and upcoming milestones in a fireside chat at BTIG's Virtual Biotechnology Conference 2024.
GlobeNewswire Inc. · Jul 30, 2024
Unveiling 4 Analyst Insights On Genelux
Genelux (NASDAQ:GNLX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $29.75, a high estimate of $32.00, and a low estimate of $25.00. This current average represents a 8.46% decrease from the previous average price target of $32.50. Exploring Analyst Ratings: An In-Depth Overview The standing of Genelux among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Bruce Jackson Benchmark Lowers Speculative Buy $25.00 $30.00 Emily Bodnar HC Wainwright & Co. Maintains Buy $32.00 - Bruce Jackson Benchmark Maintains Speculative Buy $30.00 - Emily Bodnar HC Wainwright & Co. Lowers Buy $32.00 $35.00 Key Insights: Action Taken: In response to ...Full story available on Benzinga.com
Benzinga · May 31, 2024
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
GlobeNewswire Inc. · May 24, 2024
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire Inc. · May 23, 2024
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
GlobeNewswire Inc. · May 9, 2024
Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks Investment Research · Apr 26, 2024
Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Genelux Corporation (GNLX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks Investment Research · Apr 23, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
GN
GNLX
Genelux Corporation Common Stock
Buy
Sell
Market
Limit
Soon
GNLX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any GNLX yet.
Related Tickers
Earnings